UNICREDIT BANK/CALL/BIOGEN IDEC/450/0.1/18.06.25 | Real-time BOERSE MUENCHEN 07:40:43 2024-05-17 am EDT | ||
| 0.31 EUR | 0.00% |
|
| Current month | +138.46% | ||
| 1 month | +256.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.31 | 0.00% |
| 24-05-16 | 0.31 | 0.00% |
| 24-05-15 | 0.31 | +34.78% |
| 24-05-14 | 0.23 | +4.55% |
| 24-05-13 | 0.22 | +29.41% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 07:40 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC96FD |
| ISIN | DE000HC96FD7 |
| Date issued | 2023-09-11 |
| Strike | 450 $ |
| Maturity | 2025-06-18 (397 Days) |
| Parity | 10 : 1 |
| Emission price | 1.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.35 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.23 € |
| Spread % | 53.49% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230
USD
Average target price
285.9
USD
Spread / Average Target
+24.29%
- Stock Market
- Warrants
- Warrant